Response of malignant gliomas to erlotinib
Rebecca Ireland
This article has no abstract so we have provided the first paragraph of the full text.
Long-term survival of patients with glioma has not improved, even with new treatment approaches. As the gene encoding the epidermal growth factor receptor (EGFR) is frequently amplified in gliomas, with concomitant increased levels of protein expression, inhibition of EGFR signaling could improve treatment. The EGFR inhibitor erlotinib shows clinical promise for treating malignant gliomas. In this phase I trial, Haas-Kogan et al. investigated the relationship between EGFR amplification, protein expression and response to erlotinib.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
L-DOPA, dyskinesia and striatal plasticityNature Neuroscience News and Views (01 May 2003)